MedImmune initiates Phase II asthma trial
MEDI-563, which was generated using BioWa’s Potelligent technology platform, has previously been investigated in a Phase I open-label dose-escalating study to evaluate the safety and tolerability of a
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.